leadf
logo-loader
viewInnoCan Pharma
(
CSE:INNO
)

Full interview: InnoCan Pharma signs deal with ADVA Biotechnology to produce Exosomes with CBD

InnoCann Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has signed a Letter of Intent with ADVA Bio-Technology for exosome manufacturing and development.

Bincovich telling Proactive InnoCan intends to load the produced exosomes with CBD and then will be used in the development of therapy for COVID-19 disease and other indications of the central nervous system.

Quick facts: InnoCan Pharma

Follow
CSE:INNO

Price: 1 CAD

Market Cap: $221.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Marble Financial’s subsidiary Inverite Verification records 80,000 monthly...

Marble Financial CEO Karim Nanji joined Steve Darling from Proactive to share news its subsidiary, Inverite Verification has reported achieved record growth and transaction volume milestones. Nanji telling Proactive in August the company surpassed 80,000 monthly transactions and recorded an...

10 hours, 26 minutes ago

2 min read